A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Intepirdine (Primary)
- Indications Alzheimer's disease; Dementia; Lewy body disease; Parkinson's disease
- Focus Therapeutic Use
- Sponsors Axovant Sciences
- 02 Nov 2017 According to an Axovant Sciences media release, top-line results from the study are expected in January 2018.
- 27 Sep 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
- 27 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.